Benhamou Research Group

​Our laboratory develops chemical strategies to target disease-associated RNA, RNA-binding proteins, and other challenging therapeutic targets. Combining chemical biology, medicinal chemistry, molecular and cellular biology, and computational approaches, we design small molecules, antisense oligonucleotides, and heterobifunctional chimeras to investigate and modulate disease-driving processes.

A central focus of our research is induced proximity startegy: recruiting cellular machinery to control the abundance, activity, or subcellular localization of pathogenic targets. We also develop antisense approaches to regulate RNA expression, translation, and molecular interactions, and explore targeted degradation of membrane proteins.

Across cancer, neurological, genetic, metabolic, and infectious diseases, our goal is to develop mechanistically defined chemical probes and therapeutic candidates that translate molecular insights into new treatment strategies.